Skip to main content
main-content

30-09-2020 | ESMO 2020 | Conference coverage | Video

CheckMate 9ER: Nivolumab–cabozantinib boosts advanced RCC outcomes

Andrea Apolo gives a top-line overview of the CheckMate 9ER study of nivolumab and cabozantinib, which she believes has added another option to the armamentarium for treatment-naïve, advanced renal cell carcinoma (4:00)

Read transcript

GU cancers at ESMO 2020

See all the news and expert interviews from the congress

Image Credits